Immune Tolerance in Transplantation

Immune tolerance in transplantation is the state in which a recipient's immune system accepts a graft as if it were self, without ongoing rejection and ideally without continuous immunosuppression. It is the converse of rejection and a long-standing goal of the field, rooted in the experimental demonstration that tolerance to foreign tissue can be actively acquired.

Definition

Immune tolerance in transplantation is a donor-specific state of unresponsiveness in which the recipient immune system does not reject the graft while retaining responses to other antigens, achieved through deletion of alloreactive lymphocytes (central tolerance) and their regulation or anergy in the periphery (peripheral tolerance), including suppression by regulatory T cells.

Scope

This entry covers the immunological concept of donor-specific (transplantation) tolerance: central and peripheral mechanisms, the role of regulatory T cells, and the distinction between full tolerance and the partial, drug-free graft acceptance sometimes seen clinically. It is a reference and educational description and does not provide clinical guidance or protocols.

Core questions

• What distinguishes central from peripheral mechanisms of transplantation tolerance?
• How do regulatory T cells contribute to graft acceptance?
• Why has durable, drug-free tolerance proven difficult to achieve clinically?

Key concepts

• Central tolerance (thymic deletion)
• Peripheral tolerance (anergy, regulation)
• Regulatory T cells and Foxp3
• Donor-specific unresponsiveness
• Mixed chimerism
• Operational (drug-free) tolerance

Key theories

Actively acquired tolerance

Billingham, Brent, and Medawar demonstrated that exposure to foreign cells during a critical developmental window induces lasting, antigen-specific acceptance of later grafts from the same donor, establishing tolerance as an acquired immunological state and laying the conceptual foundation for transplantation tolerance.

Regulatory T-cell control

A dedicated population of regulatory T cells, defined by the transcription factor Foxp3, actively suppresses immune responses; these cells can restrain alloreactivity and are central to peripheral mechanisms of transplantation tolerance.

Mechanisms

Tolerance arises through complementary mechanisms. Central tolerance deletes strongly self- or allo-reactive lymphocytes during development in the thymus, where Foxp3-expressing regulatory T cells are also selected. Peripheral tolerance acts on mature lymphocytes through clonal deletion, functional inactivation (anergy), and active suppression by regulatory T cells that restrain alloreactive responses. Experimentally, establishing donor-derived haematopoietic cells in the recipient (mixed chimerism) can promote durable donor-specific tolerance. In clinical transplantation, lifelong immunosuppression substitutes for tolerance in most recipients, although rare cases of stable graft function after stopping drugs (operational tolerance) show that tolerance is biologically attainable.

Clinical relevance

Tolerance frames the rationale for immunosuppression and the long-term aspiration to reduce or eliminate it; understanding regulatory cells and chimerism is central to interpreting tolerance research and trials. This entry is conceptual and descriptive and does not recommend withdrawing immunosuppression or any individualized course of treatment.

History

The modern concept of acquired immunological tolerance was established by Billingham, Brent, and Medawar in 1953 and built on Burnet and Fenner's earlier theoretical predictions. Subsequent decades clarified central thymic deletion, the discovery of regulatory T cells and their Foxp3 master regulator, and experimental strategies such as mixed chimerism, reframing tolerance from a laboratory phenomenon into a translational goal.

Debates

Can durable clinical tolerance be achieved safely?

Strategies such as regulatory-cell therapy and mixed chimerism can induce donor-specific tolerance experimentally, but translating them into safe, reliable drug-free tolerance in patients remains unproven and is an active area of investigation.

Key figures

• Peter Medawar
• Rupert Billingham
• Leslie Brent
• Shimon Sakaguchi
• Kathryn Wood

Seminal works

• billingham-1953
• hori-2003
• wood-2012

Frequently asked questions

What is transplantation tolerance?

It is a state in which the recipient's immune system accepts a specific donor's graft without rejecting it and ideally without ongoing immunosuppression, while still responding normally to other antigens.

Why don't most transplant recipients have true tolerance?

Durable donor-specific tolerance is difficult to induce reliably and safely, so most recipients depend on continuous immunosuppression instead; stable drug-free graft function (operational tolerance) is observed only in a minority.